Greene Barry E 4

What Happened Barry E. Greene, a director of Karyopharm Therapeutics Inc. (KPTI), was awarded 15,508 restricted stock units (RSUs) on May 21, 2026. The RSUs were granted at $0.00 (no cash paid) and will convert one-for-one into common stock when delivered. This is an equity award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: May 21, 2026; Form 4 filed May 26, 2026 (five days after the grant).
• Grant: 15,508 RSUs @ $0.00; reported value $0 on the grant line.
• Vesting/delivery: RSUs vest 100% on May 21, 2027, but delivery of shares is deferred until the earlier of (a) the director’s separation from service or (b) a change-in-control event (footnote F1).
• Reverse split adjustment: amounts reflect a one-for-fifteen reverse stock split effective Feb 25, 2025 (footnote F2).
• Shares owned after the transaction: not specified in the provided filing.
• Filing timeliness: Form 4 was filed five days after the transaction; Form 4s are generally required within 2 business days, so this appears later than the usual deadline.

Context RSU awards are a retention/compensation tool for directors and do not represent an immediate sale or cash investment. Because delivery is deferred until separation or a change in control, these RSUs do not provide immediate liquidity and indicate a future entitlement to company shares if vesting conditions are met.